Three deep-science platforms: potential nuclear-grade graphite, graphene coatings, and aptamer biosciences: operating on a single client-funded development-on-demand CRO model that owns the IP and minimises dilution. We believe every potential re-rating catalyst remains ahead.
We believe three structural conditions have converged simultaneously: geopolitical tailwinds, commercially-ready science, and a proven model.
Export licensing restrictions introduced in 2023 triggered over $1.8B in North American capacity announcements. Emerging pathogen threats have put significant US government biosecurity funding in play. Supply chain sovereignty is now a national security mandate across all Five Eyes nations: written into procurement frameworks, not just policy papers.
Thirty years of aptamer research is now commercially deployable for the first time. Triera has the team and the IP that makes that possible. Graphene coatings are moving from laboratory to industrial scale. Albany graphite has demonstrated nuclear-grade purity through independent testing. These are not projections: they are published, peer-reviewed, independently verified results.
The client-funded CRO model: industry brings the problem, Zentek develops the solution and owns the IP: has created multi-billion dollar companies in pharma (Charles River, ICON) and specialty materials (NanoXplore, Aptamer Group). Non-dilutive government funding offsets 35–80% of R&D cost. No manufacturing capex required. Zentek is currently priced at ~6×: specialty materials and IP platform peers trade at 17×+.
We believe three concurrent tailwinds are closing the valuation gap. Specialty materials and IP platform peers trade at 17×+. The three platforms together, each at first revenue, would justify a meaningful re-rating.
Zentek today sits at the bottom of this stack: priced as if it is only a mining company. The three platforms it operates are a materials CRO, an IP licensing engine, and a biotech CRO. As each platform generates its first commercial revenue: a coatings development contract, a nuclear supply agreement, a Triera diagnostic licence: the re-rating from mining multiple to specialty materials multiple begins. None of these catalysts have yet been priced in. Every one of them remains ahead.
The three platforms are structurally independent: different markets, different buyers, different commercial triggers. Any one of them achieving commercial traction is a re-rating event. All three in motion simultaneously is the full thesis.
These are actual observed market capitalisations of named public companies at or near comparable development milestones: not projections.
NMG entered at C$12M pre-scoping. Zentek enters ahead of that analogue at an equivalent milestone. Every subsequent de-risking step triggered a material re-rating. All those catalysts remain ahead of Zentek.
Specialty graphene materials companies at EBITDA breakeven trade between C$100+M and A$210M. The coatings platform alone, at first profitability, would justify a re-rating from current levels based on observed sector comparables. Sector multiple: 8–15× EBITDA.
Biotech CRO peers at C$5M revenue trade at C$120M+. Triera has stronger IP and academic validation than Aptamer Group at an equivalent stage. Sector multiple: 4–8× revenue or 15–25× EBITDA.
An integrated platform operating across all three sectors: graphite, coatings, and aptamers: would have a combined analogue composite of approximately C$168M at early stage, C$665M at mid stage, and C$1.1B at peak stage, based on actual observed market caps of sector analogues (NMG, NanoXplore, Aptamer Group). These are not projections of Zentek's future market cap.
Coming soon · request via investor relations
All Canadian continuous disclosure documents
US furnishing · foreign private issuer · IFRS
All public disclosures via ACCESS Newswire
Toronto Stock Exchange Venture market data
Nasdaq Capital Market · Nasdaq: ZTEK
Zentek is actively seeking strategic partners and long-term investors who recognise the convergence of critical minerals supply chain urgency, advanced air quality requirements, and next-generation therapeutic development. If you are exploring any of these areas, we would like to hear from you.
This page contains forward-looking information within the meaning of applicable Canadian and United States securities laws, including statements about market opportunities, development timelines, potential revenue, valuation multiples, and funding sources. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied. Zentek Ltd. (TSX-V: ZEN / Nasdaq: ZTEK) is a reporting issuer in Canada and a foreign private issuer in the United States, filing financial reports on Form 6-K under IFRS in Canadian dollars.
Analogue comparisons on this page present actual reported market capitalisations of named third-party public companies (NMG, Syrah Resources, NanoXplore, GMG, Aptamer Group) at or near stated development milestones. These are historical observations only and are not projections of Zentek's future market capitalisation, share price, or financial performance. Zentek's current market capitalisation is cited as a statement of fact as of the date indicated. Nothing on this page constitutes a mineral resource or reserve estimate under NI 43-101, a medical claim, financial advice, or an offer or solicitation to buy or sell securities. Readers are referred to Zentek's continuous disclosure documents on SEDAR+ and EDGAR for complete risk factor disclosure. Full company disclaimer →
Three interactive tools built to help investors, analysts, and technical partners understand the Albany deposit, its economics, and the global graphite market context.